Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.8.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 25,496 $ 18,941
Marketable securities-available for sale, at fair value 7,180
Prepaid expenses and other 947 1,019
Total current assets 26,443 27,140
Property and equipment, net 91 150
Restricted cash 89 89
Intangible asset 120 120
Security deposits 11 11
Total assets 26,754 27,510
Current liabilities:    
Accounts payable 1,296 872
Accrued expenses 830 1,244
Total current liabilities 2,126 2,116
Deferred rent payable 12 33
Total liabilities 2,138 2,149
Commitments (See Note 9)  
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized; 7,830,040 and 3,919,181 shares issued and outstanding as of December 31, 2017 and 2016, respectively, 2,496 shares to be issued as of December 31, 2016 8 4
Additional paid in capital 186,983 166,604
Accumulated deficit (162,363) (141,240)
Accumulated other comprehensive loss (12) (7)
Total stockholders' equity 24,616 25,361
Total liabilities and stockholders' equity $ 26,754 $ 27,510
v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
COSTS AND EXPENSES:    
Research and development $ 13,342 $ 28,533
General and administrative 7,949 10,436
Total costs and expenses 21,291 38,969
Operating loss (21,291) (38,969)
Interest income, net 168 127
NET LOSS $ (21,123) $ (38,842)
Net loss per common share, basic and diluted (in dollars per share) $ (3.17) $ (15.41)
Weighted average common shares outstanding, basic and diluted (in shares) 6,665,091 2,521,016
v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (21,123) $ (38,842)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 70 206
Stock-based compensation 1,790 3,266
Loss on disposal of property and equipment 133
Changes in operating assets and liabilities:    
Prepaid expenses 72 2,370
Accounts payable 424 (2,185)
Accrued expenses and deferred rent (361) (2,261)
Net cash used in operating activities (19,128) (37,313)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (5) (66)
Maturities of marketable securities 7,174 16,615
Net cash provided by investing activities 7,169 16,549
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 14
Proceeds, net of expenses of $1,183 and $1,866, from sale of common stock 18,505 20,498
Net cash provided by financing activities 18,519 20,498
Effect of currency rate change on cash (5) (11)
Net increase (decrease) in cash, cash equivalents and restricted cash 6,555 (277)
Cash, cash equivalents and restricted cash, beginning of the year 19,030 19,307
Cash, cash equivalents and restricted cash, end of year 25,585 19,030
Non cash financing activities:    
Issuance of common stock under employee stock purchase plan $ 74 $ 167